Functional analysis of proteins involved in Plasmodium falciparum merozoite invasion of red blood cells  by Cowman, Alan F. et al.
Minireview
Functional analysis of proteins involved in Plasmodium falciparum
merozoite invasion of red blood cells
Alan F. Cowmana;*, Deborah L. Baldia, Julie Healera, Kerry E. Millsa,
Rebecca A. O’Donnellb, Michael B. Reeda, Tony Trigliaa, Mark E. Wickhama,
Brendan S. Crabbb
aThe Walter and Eliza Hall Institute of Medical Research, P.O. Royal Melbourne Hospital, Melbourne, Vic. 3050, Australia
bDepartment of Microbiology and Immunology, The University of Melbourne, Melbourne, Vic., Australia
Received 31 May 2000
Edited by Gunnar von Heijne
Abstract Plasmodium falciparum causes the most lethal form
of malaria in humans and is responsible for over two million
deaths per year. The development of a vaccine against this
parasite is an urgent priority and potential protein targets include
those on the surface of the asexual merozoite stage, the form that
invades the host erythrocyte. The development of methods to
transfect P. falciparum has enabled the construction of gain-of-
function and loss-of-function mutants and provided new strate-
gies to analyse the role of parasite proteins. In this review, we
describe the use of this technology to examine the role of
merozoite antigens in erythrocyte invasion and to address their
potential as vaccine candidates. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Malaria has been a signi¢cant burden on humans through-
out recorded history and this continues in modern times. The
ability of the parasite to develop resistance to antimalarial
drugs and the absence of a suitable vaccine to control the
disease ensures that malaria remains a major global problem.
Plasmodium falciparum causes the most severe form of malaria
in humans and is responsible for 200^300 million infections
per year. Over two million infected people die as a result of
the disease annually. The development of a vaccine is a prior-
ity, and potential vaccines are being targeted to various stages
of the parasite life cycle. The asexual merozoite has been a
particular focus in recent times. The merozoite form of the
asexual life cycle in the blood stage attaches to the surface of
the red blood cell (RBC) thus initiating the invasion process
of this host cell. Inside the RBC the parasite replicates and
matures into a schizont form which eventually ruptures to
release new merozoites and complete the blood stage cycle.
Merozoite antigens are exposed to the immune system and
consequently these proteins are potential vaccine candidates.
Many of these proteins are thought to play a role in merozoite
invasion of RBCs but the details of their function remain
sketchy at best.
Merozoite invasion takes place following initial interaction
with the RBC surface followed by re-orientation to allow the
apical end to interact with the membrane of the host cell (Fig.
1). The contents of the apical organelles, the rhoptries and
micronemes, are expelled and a tight junction is formed be-
tween the merozoite surface and the RBC membrane [1]. The
tight junction moves along the surface of the merozoite, pos-
sibly via force generated by an actin myosin motor, until the
membrane fuses at the posterior end of the parasite. This
results in the formation of a parasitophorous vacuole contain-
ing the newly invaded merozoite. Many proteins appear to be
involved in this complex invasion process, although very little
is known about the particular role of any individual protein.
One of these proteins, merozoite surface protein 1 (MSP1),
has been hypothesised to be involved in the initial interaction
of the merozoite with the RBC surface [2,3]. As its name
implies, this GPI-anchored protein is found on the surface
of the merozoite. This localisation is shared with a number
of other GPI-anchored proteins including MSP2 [4], MSP4 [5]
and MSP5 [6]. Apical membrane antigen 1 (AMA1) is an
integral membrane protein that is initially localised to the
neck of the rhoptries although after schizont rupture the pro-
tein spreads onto the merozoite surface [7^11]. The function
of AMA1 is not currently known. Within the rhoptries, a
number of proteins have been identi¢ed that may be involved
in invasion. This includes the low molecular weight complex
that consists of the rhoptry-associated proteins 1 and 2 (RAP1
and RAP2) [12,13] as well as a poorly characterised protein
RAP3 [14]. This soluble protein complex is expelled from the
rhoptries during invasion and is carried through into the para-
sitophorous vacuole with the merozoite [15]. The erythrocyte-
binding antigen 175 (EBA175) is located in the micronemes
and has been shown to bind to the RBC surface molecule
glycophorin A in a sialic acid-dependent manner [16^18].
The ability of each of these P. falciparum antigens to elicit a
protective immune response has led to their consideration as
vaccine candidates. However, with the possible exception of
EBA175, little is known about the role of any of these anti-
gens in the invasion process. To address this issue, we have
used transfection approaches in P. falciparum and this has not
only provided important information on function, but may
also address their validity as vaccine candidates [15].
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2. Analysis of merozoite invasion using gene disruption
The development of transfection in P. falciparum has cre-
ated the possibility to construct loss-of-function mutants by
gene disruption [19^21]. It may be expected that genes encod-
ing invasion-related proteins would be essential and therefore
di⁄cult to disrupt. However, merozoite invasion pathways
appear to be degenerate in nature, involving di¡erent parasite
ligands and RBC receptors [22]. Therefore it may in some
cases be possible to disrupt particular invasion pathways with-
out compromising the viability of the parasite. An indication
that this inference may be correct lay in the fact that several
P. falciparum parasite lines are able to invade RBCs via multi-
ple pathways, while others appear to lack some of these in-
vasion routes [22,23].
We have attempted to disrupt several genes that have been
linked to the invasion process. Not surprisingly, many of these
appear to be lethal or severely deleterious (Table 1). Interest-
ingly, it was possible to disrupt the RAP1 gene and this re-
sulted in parasites that express severely truncated forms of
RAP1 [15]. Truncated RAP1 still tra⁄cs to the rhoptries
but can no longer complex with RAP2. In these parasites
RAP2 is found in a compartment resembling the lumen of
the endoplasmic reticulum rather than in the rhoptries. These
results suggest that a function of RAP1 is to localise RAP2 to
the rhoptries. This also supports the hypothesis that rhoptry
biogenesis is dependent, at least in part, on the secretory path-
way in the parasite [24].
EBA175 is involved in the glycophorin A-dependent inva-
sion pathway and disruption of this gene was performed to
address the role of the conserved 3P cysteine-rich region, the
transmembrane and the cytoplasmic domains by deletion of
these regions [25]. Such a truncation had no measurable e¡ect
on the level of EBA175 protein expression or its subcellular
localisation in the micronemes. Similarly, there was no impair-
ment in the ability of soluble EBA175 to be released into the
culture supernatant following schizont rupture. These experi-
ments have shown that the 3P Cys-rich region, transmembrane
and cytoplasmic domains of EBA175 are not essential for
merozoite invasion. However, analysis of RBC invasion via
the EBA175/glycophorin A route suggested that this pathway
was disrupted to such a degree that the mutant lines have
undergone a stable switch in invasion phenotype to a sialic
acid-independent pathway accounting for 85% of normal mer-
ozoite invasion. This suggests that truncation of the C-termi-
nus of EBA175 leads to functional inactivation. These data
demonstrate that the P. falciparum parasite has the ability to
utilise alternative pathways for invasion of RBCs. This prop-
erty would undoubtedly provide a substantial survival advant-
age to the parasite in terms of overcoming host receptor het-
erogeneity and/or immune pressure.
It is clear that it is not possible, with current transfection
technology in P. falciparum, to disrupt many genes believed to
be important in merozoite invasion. Attempts to disrupt most
of the genes shown in Table 1 have not been successful ; how-
ever, this could be due to a number of reasons. Firstly, the
D10 parasite, which was used in the majority of gene disrup-
tion experiments, lacks at least one of the known invasion
pathways [22]. It is possible that P. falciparum merozoites
require a minimum number of ligands and pathways for suc-
cessful invasion of the RBC. Consequently, it will be impor-
tant to test gene disruption in other parasite lines with a
broader range of invasion pathways. Secondly, the current
transfection procedure results in persistence of a circular
form of the transfection plasmids. As a result, selection of
parasites with integrated copies of the plasmid in the gene
of interest involves cycling of transfectants on and o¡ drug
[19,20,26]. However, if the gene disruption event results in a
parasite capable of invading but at a reduced e⁄ciency, cy-
cling will be ine¡ective in selecting them from the population
carrying the episomal plasmid. To overcome this it will be
essential to develop plasmid vectors containing negative se-
lectable markers such as cytidine deaminase and thymidine
kinase, thus allowing the removal of the persisting episomal
plasmid. Finally, the gene of interest may be essential for
RBC invasion. In this case, it will not be possible to create
gene disruptions using normal techniques and an inducible
promoter system will be required. Such methods, such as
the tetracycline repressor/operator system [27], allow activa-
tion and repression of gene expression in a controlled manner.
Two examples of essential genes appear to be the MSP1 [28]
and AMA1 (Triglia et al., submitted). Both of these genes can
be targeted by transfection plasmids only if the recombination
events result in gene reconstitution and thus wild-type protein
expression.
The ability to disrupt genes believed to be involved in mer-
ozoite invasion clearly shows that they are not absolutely
essential for this process in vitro. For example, RAP1 together
Table 1
Gene targeting of genes encoding P. falciparum merozoite antigens
Gene Construct designa End
pointb
Reference
MSP1 KO NHIc [28]
MSP1 3P replacement HId [28]
MSP2 KO NHI Cowman et al., unpublished
MSP2 3P replacement HI Wickham et al., unpublished
MSP3 KO under
way
Mills et al., unpublished
MSP3 3P replacement HI Mills et al., unpublished
MSP4 KO NHI Cowman et al., unpublished
MSP5 KO NHI Cowman et al., unpublished
RAP1 KO HI [15]
RAP2 KO NHI O’Donnell et al.,
unpublished
RhopH3 KO NHI O’Donnell et al.,
unpublished
Ag512 KO NHI Baldi et al., unpublished
AMA1 KO NHI Triglia et al., submitted
AMA1 3P replacement HI Triglia et al., submitted
EBA175 KO NHI Baldi et al., unpublished
EBA175e KO HI [25]
S-antigen KO NHI Cowman et al., unpublished
ABRA KO NHI Cowman et al., unpublished
aPlasmids for gene targeting were based on either the pHC1 [21] or
pHH1 [45] plasmids. These were designed to either ‘knock out’
(KO) the gene of interest or to integrate into the gene in a manner
that would retain gene function (3P replacement). Construct design
and integration procedures were essentially as described in
[21,28,46].
bEnd point represents result after three to ¢ve drug cycles for inte-
gration (4^6 months of continuous culture). Re£ects bulk parasite
population as observed by Southern blot experiments.
cNHI: no homologous integration. Usually manifest as episomal
forms that remained after extensive culturing, however, occasionally
non-homologous integration was observed.
dHI: homologous integration.
eThis transfection was carried out in the W2mef parasite line while
all others were performed in D10.
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with RAP2 have been viewed as important vaccine candidates
as they can partially protect Saimiri monkeys from challenge
with P. falciparum [13,29]. Furthermore, monoclonal antibod-
ies speci¢c for RAP1 can inhibit invasion into RBCs [30^32].
The ability to disrupt RAP1 and as a consequence the RAP1/
RAP2/RAP3 complex demonstrates that it is not essential for
invasion and growth of P. falciparum in human RBCs. While
in vivo studies remain to be carried out, this evidence must
temper enthusiasm for RAP antigens as vaccine candidates. It
is possible that inhibition of merozoite invasion by RAP1
antibodies occurs via steric hindrance of the invasion process
rather than speci¢c inhibition of an essential RAP1 function.
This would explain the ability of RAP1 and RAP2 to protect
monkeys against P. falciparum challenge [13,29]. These ¢nd-
ings raise the possibility that breakthrough parasites could
arise that can survive in the absence of functional RAP1.
3. What does cross-species complementation of merozoite
proteins tell us about function, protective immunity and
potential as a vaccine?
Plasmodium species generally show host speci¢city with re-
spect to RBC invasion. However, some parasites show an
ability to invade RBCs from di¡erent mammalian hosts.
For example P. falciparum, which normally invades human
RBCs, can also invade mouse RBCs, albeit at a greatly re-
duced e⁄ciency [33]. Homologues of some merozoite proteins,
for instance MSP1 and AMA1, are found across the Plasmo-
dia and it is presumed that these molecules are at least in part
functionally conserved. It is now possible to perform cross-
species complementation experiments in order to explore
questions relating to function and protective immunity.
The C-terminal region of P. falciparum merozoite surface
protein 1 (MSP119) is currently a leading malaria vaccine can-
didate [34]. The interest in this molecule stems from the ¢nd-
ing that antibodies to the epidermal growth factor (EGF)-like
domains of MSP119 are associated with clinical immunity to
P. falciparum [35,36]. Also, active immunisation with MSP119-
based vaccines has been shown to provide a degree of protec-
tion in various experimental systems [37,38]. These studies,
together with the knowledge that EGF-like domains in other
molecules possess critical binding functions, suggest an impor-
tant role for this protein in merozoite invasion of RBCs. De-
spite extensive molecular epidemiological investigations, it is
signi¢cant that only limited sequence polymorphism has been
identi¢ed in P. falciparum MSP119 [39,40]. This implies that
its sequence is functionally constrained and is used in support
of the use of MSP119 as a vaccine.
Fig. 1. Invasion of the merozoite form of P. falciparum into red blood cells. A: Diagrammatic representation of a malaria merozoite shows
some important structural features and the localisation of some P. falciparum antigens. Rh, rhoptries; N, nucleus; IM, inner membrane; Mt,
mitochondria; Pr, polar rings; Ap, apical end; Pl, apicoplast or plastid; M, microtubules; Mn, micronemes; AMA1, apical membrane antigen
1; MSP1, 2, 3, 4, 5, merozoite surface proteins 1, 2, 3, 4, 5; EBA175, erythrocyte binding antigen 175; RAP1, 2, rhoptry-associated protein 1,
2; RhopH3; ABRA; S-antigen. B: Schematic representation of some of the major morphological events associated with merozoite invasion.
(A) Attachment; (B) apical reorientation; (C) junction formation and the beginning of rhoptry discharge; (D and E) penetration of the mero-
zoite past the tight junction into a forming parasitophorous vacuole; (F and G) pinching o¡ of the junction, and resealing of the red blood
cell membrane. The surface coat of the merozoite is progressively stripped o¡ as it moves through the tight junction (D to F). The membrane
surrounding the fully invaded merozoite is termed the parasitophorous vacuole membrane.
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In light of the sequence conservation of P. falciparum
MSP119, it was somewhat surprising to ¢nd that the
MSP119 of the rodent parasite P. chabaudi can complement
the function of P. falciparum MSP119, despite the fact that
they are highly divergent in sequence [28]. This implies that
the role of MSP119 in RBC invasion is conserved across dis-
tantly related Plasmodium species and that the sequence of P.
falciparum MSP119 is not tightly constrained by function as
suggested by sequence analysis. This has implications for the
use of this molecule in malaria vaccines. Firstly, it is impor-
tant to consider the possibility that ‘escape’ mutant parasites,
which will presumably acquire point mutations in MSP119,
will be selected in vaccinated individuals. Structural analyses
of MSP119 have revealed a tight association between the two
EGF domains, suggesting that individual point mutations
were likely to have consequences for the structural integrity
of the domain [41,42]. Therefore, it is possible that such events
may require complementary changes elsewhere in the mole-
cule. As a result, point mutations may not accumulate easily
in response to immune pressure. However, given our observa-
tion that P. falciparum can invade e⁄ciently using a divergent
MSP119 domain, it is now conceivable that if MSP119 ‘escape’
mutant parasites do arise in response to vaccination, these
may not show a reduced ‘¢tness’ over wild-type parasites.
Widespread immunisation with e¡ective MSP119-based vac-
cines is likely to place much greater selection pressure on
the parasite population than is normally evident in infected
individuals. This will raise the possibility of such vaccines
selecting for P. falciparum parasites with antigenically diver-
gent MSP119 domains.
AMA1 is also a leading asexual blood stage protein being
considered for inclusion in a malaria vaccine against P. falci-
parum. It was not possible to disrupt the PfAMA1 gene using
PfAMA1 gene ‘knockout’ plasmids. However, the AMA1
gene could be targeted by homologous recombination when
this recombination results in gene reconstitution. These ex-
periments have suggested that PfAMA1 is critical, perhaps
essential, for blood stage growth. Despite this we have com-
plemented the function of the P. falciparum AMA1 (PfA-
MA1) with a divergent AMA1 transgene from P. chabaudi
(PcAMA1) (Triglia et al., submitted). Importantly, PcAMA1
expression in P. falciparum provides trans-species complemen-
tation to at least 35% of the function of endogenous PfAMA1
in human RBCs. Furthermore, expression of this transgene in
P. falciparum leads to more e⁄cient invasion of murine RBCs.
These results indicate an important role for AMA1 in the
invasion of RBCs across divergent Plasmodium species and
support the development of this molecule as a malaria vac-
cine.
4. Concluding remarks
The ability to make loss-of-function and gain-of-function
mutants is now assisting dissection of the role of P. falciparum
proteins in RBC invasion and in providing protective immun-
ity. For instance, disruption of genes encoding proteins that
are not essential for invasion in vitro, such as EBA175 and
RAP1, has given insights into their function in di¡erent in-
vasion pathways. However, this knowledge, together with the
many previous studies that employed biochemical methodol-
ogies and other biological approaches, has only scratched
the surface of our understanding of the molecular basis of
P. falciparum merozoite invasion. Not only is there still
much to be learnt about the molecules with which we are
familiar, but with the P. falciparum genome project approach-
ing completion many new molecules potentially relevant to
this process are being identi¢ed [43,44]. For example, the ge-
nome possesses several genes homologous to EBA175 that are
clear candidates for an involvement in alternative invasion
pathways.
The use of microarray, proteomic and potentially other
‘whole organism’ analytical tools will be essential in utilising
the genetic information in the context of understanding mer-
ozoite invasion pathways. Such technologies are likely to
prove particularly useful in the identi¢cation of signalling
molecules that regulate processes such as the ontogeny of
merozoite antigen expression and perhaps also invasion path-
way switching. Improved transfection methodologies are also
clearly needed. The availability of inducible promoter systems
to derive conditional lethal mutants and of episomal suicide
plasmids would greatly assist in the functional analysis of
proteins that are essential to P. falciparum blood stage
growth.
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